Compare Inovio Pharmaceuticals Inc (INO) vs KraneShares Electric Vehicles and Future Mobility (KARS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs KraneShares Electric Vehicles and Future Mobility — how do they compare? Inovio Pharmaceuticals Inc trades at $0.76 (market cap $78.55M), while KraneShares Electric Vehicles and Future Mobility trades at $30.99. The key difference: KraneShares Electric Vehicles and Future Mobility is trading nearer its 52-week high, Inovio Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| INO | KARS | |
|---|---|---|
Market Cap | $78.55M | — |
Sector | Health | Sector/Thematic |
52-Week High | $2.87 | $38.01 |
52-Week Low | $0.66 | $25.59 |
Enterprise Value | $49.56M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INO trades at $0.772, up 4.83% in the last 24 hours, but technical indicators signal a bearish trend. The company shows minimal revenue of $65,340 in 2025 with a net loss of $84.95 million, though it has beaten EPS estimates in recent quarters. Key developments include an upcoming Q2 2026 earnings report on August 12, 2026, and a pending FDA decision on INO-3107 by October 30, 2026.
The outlook hinges on FDA approval of INO-3107, with a consensus price target of $3.25 implying significant upside. However, high cash burn, negative margins, and legal scrutiny pose substantial risks. Investors should weigh the binary event against persistent financial challenges.
KARS trades at $30.99, down 0.42% on the day, with a bullish technical signal driven by moving averages and oscillators. The stock faces resistance near $31-$32, while support lies at $30-$29. Recent news highlights global EV sales growth, with China targeting 30% NEV fleet by 2030 and Europe seeing demand surges from high fuel prices, though U.S. adoption lags.
The outlook for KARS is supported by EV industry tailwinds, but risks include competitive pressures from Chinese automakers and regulatory delays. Analyst sentiment is mixed, with technical indicators suggesting near-term consolidation. Institutional interest may hinge on sustained EV adoption trends and execution against growth targets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About KraneShares Electric Vehicles and Future Mobility
KARS invests in the global electric vehicle ecosystem and future mobility. It tracks the Bloomberg Electric Vehicles Index, providing exposure to EV manufacturers, battery technology, and lithium miners like Tesla, BYD, and Albemarle.
Read more on KARS →
